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New findings in this issue of Cell Stem Cell by Qian et al. (2007) and Yoshihara et al. (2007) reveal that
thrombopoietin modulates hematopoietic stem cell (HSC) cell-cycle progression at the osteoblast
surface, linking a single cytokine with a specific postnatal niche cell. These observations indicate that
simultaneous stimulation and suspension in a G0 state are critical for maintenance of the HSC pool.Clinical observations over the past 40
years in patients undergoing hemato-
poietic stem cell (HSC) transplants
have suggested a close relationship
between thrombopoiesis and stem
cell activity. Delayed or inadequate
platelet recoveries are the most sensi-
tive indicators of inadequate numbers
of transplanted stem cells, and throm-
bocytopenia is the first sign of graft
failure (Ninan et al., 2007). When
thrombopoietin (THPO) was first
cloned by its binding to the Mpl recep-
tor and characterized by its essential
role in stimulating thrombopoiesis, it
was thus no surprise that THPO was
also found to have a key role in HSC
maintenance and expansion (Sitnicka
et al., 1996).
Purified recombinant THPO itself
was found to synergize with other pro-
liferative cytokines to support HSC
proliferation in vitro. Because THPO,
like other cytokines such as SCF and
IL-3, activates MAPK, AKT, and STAT
pathways, such interactions might
suggest overlapping, redundant func-
tions (Dorsch et al., 1995). However,
the finding that Mpl/ mice are stem
cell deficient suggested that THPO
might have an important and unique
role not shared by other cytokines (Al-
exander et al., 1996).
In this issue of Cell Stem Cell, Qian
et al. (2007) begin by measuring HSC
numbers both before and throughout
life in Thpo/ versus normal mice.
They find that postnatal HSCs are
normal, both in number (as measured
by cell surface phenotype) and in po-
tency following stem cell transplanta-
tion. However, HSC numbers begin to
decline within a few weeks after birthand continue to do so throughout life,
resulting in a 1503 reduction. They go
on to show that Thpo/ HSCs show
increased cycling, and reduced levels
of the CDKIs p57kip2 and p19ink4D.
These data indicate that postnatal
HSCs, unlike fetal HSCs, are THPOde-
pendent for their survival and mainte-
nance. Again, this effect was observed
both at baseline, as measured by cell
surface phenotype, and functionally
following HSC transplantation. In addi-
tion, they found that this THPO effect
on HSC survival and maintenance is
not Bcl-2 dependent.
Although the authors do not specu-
late on what distinguishes prenatal
from postnatal HSC THPO depen-
dence, one clear difference between
hematopoiesis before and after birth
is the transition of HSCs to the bone
marrow microenvironment. One might
therefore hypothesize that if THPO
has a unique postnatal role in the life
of HSCs, then this role would be ex-
pressed directly in the topography of
the bone marrow microenvironment,
through interactionwith theMpl recep-
tor on unique BM niche cells. Yoshi-
hara et al. (2007) now present data
supporting precisely this notion, that
the THPO-Mpl axis is anatomically
and functionally expressed between
HSCs and the osteoblast surface in
the bone marrow. In their precise anal-
ysis, they first show that long-term
repopulating hematopoietic stem cells
(LT-HSCs) that express Mpl are largely
in G0 and are located in apposition to
THPO+ osteoblasts. They then show
that THPO treatment increases HSC
expression of CDKIs and increases
the entry of HSCs into G0 prior to theirCell Stem Cell 1,proliferation. In contrast, treatment
with neutralizing anti-Mpl antibody
blocks restraint of in vivo HSCs in G0,
and functionally releases them from
their microniches, allowing their dis-
placement by transplantedHSCs. Their
results therefore support a key role for
THPO in supporting HSC quiescence
and further allude to key roles for
osteoblasts in providing these signals
in vivo.
These two findings provide tentative
answers to several important ques-
tions in HSC biology but leave other
key issues still open to exploration.
On the plus side of the ledger, these
results provide the first molecular
answer to what is the key HSC signal
provided in the BMmicroenvironment,
andwhere. Similarly, if THPO is the key
HSC retentive signal provided by oste-
oblasts, this might explain why dele-
tion of osteoblasts in vivo does not re-
sult in immediate loss of HSCs, but
rather HSC redistribution out of the
marrow, with HSC loss only occurring
slowly. Still mysterious, however, is
that efforts to date to culture and ex-
pand HSCs in vivo without loss of
HSC potency, even with THPO, have
met with limited success. Could there
be other signals produced by osteo-
blasts, or even other cells within the
BM niche, that are also required for
HSC maintenance and proliferation?
One surprising finding is that adher-
ence to the niche seems to be multi-
factorial, or at least extremely delicate.
Czechowicz et al. have recently found
that HSCs can be functionally dis-
placed from their niches by in vivo
treatment with anti-c-kit antibody
(Czechowicz et al., 2007). OsteopontinDecember 2007 ª2007 Elsevier Inc. 599
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HSC homing and adhesion to the niche
(Stier et al., 2005), while blockade of
CD44 appears to block adhesion of
leukemic stem cells to the bone mar-
row microenvironment (Jin et al.,
2006).
Given the complex function of the
bone marrow stem cell niche, could
these critical adhesive and functional
signals from the niche cells be induced
only by the retrograde secretion or lo-
cal presentation of specific molecules
from HSCs? I.e., might HSCs con-
dition their niche (Taichman et al.,
2007)? Similarly, given these data,
why are prenatal HSCs THPO inde-
pendent? Are homologous signals,
which activate similar survival path-
ways in HSCs, secreted by embryonic
and fetal liver fibroblasts, or are fetal
HSCs fundamentally different from
postnatal HSCs? Similarly, one must
ask whether similar paradigms apply
to stem cells for other tissues, in other
organ-specific niches? And of course,
at a molecular level, why is mainte-
nance of a G0 pool required for long-
term support of HSC numbers?
Finally, it is always worthwhile to at-
tempt to draw tentative hypothesesNew Tools for Ge
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The introduction of human embryonic
stem cell technology into the scientific
mainstream in 1998 brought with it the
possibility of cell-based therapy for
600 Cell Stem Cell 1, December 2007 ª2from elegant studies such as these
into the world of clinical hematology.
Would the provision of the proper
pharmacologic concentration of THPO
actually accelerate or quantitatively
enhance HSC engraftment after trans-
plantation? Conversely, would provi-
sion of anti-THPO antibody to patients
with acute leukemia release their
leukemic HSCs from the protection of
G0 retention, thus rendering them
more susceptible to anti-leukemic
ablative therapies? Such queries
could be directly tested in current im-
munodeficient mouse models, with
the potential for decisive clinical appli-
cation.
In summary, Qian et al. and Yoshi-
hara et al. present elegant and com-
pelling new data demonstrating a key
role for THPO in the maintenance of
the long-term repopulating, quiescent
HSC pool and furthermore suggest
that provision of THPO is at least one
of the unique contributions of osteo-
blasts after the transition of hemato-
poiesis from fetal liver to the bone
marrow. Clearly osteoblasts have
paid close attention to their musical
roots and ‘‘hold on loosely, but don’t
let G0.’’nome Modificati
onic Stem Cells
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ral Hospital, 55 Fruit Street, Boston, MA 021
reet, Cambridge, MA 02138, USA
nerative Medicine, Cardiovascular Research
n, MA 02114, USA
ements in gene editing technolog
or development. The systems dev
2007) in Nature Biotechnology,
Cells, have the potential to advan
conditions not treatable with available
pharmaceutical agents (Thomson
et al., 1998). Yet, 10 years on, the
stem cell field does not appear poised
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